Search

Purpose: The present work aimed at conducting a real-world data analysis on the management costs and survival analysis comparing data from non-small-cell lung cancer (NSCLC) cases diagnosed in the Veneto region before (2015) and after (2017) the implementation of a regional diagnostic and therapeutic pathway including all new diagnostic and therapeutic strategies., Method: This study considered 254 incidental cases of NSCLC in 2015 and 228 in 2017 within the territory of the Padua province (Italy), as recorded by the Veneto Cancer Registry. Tobit regression analysis was performed to verify if total and each item costs (2 years after NSCLC diagnosis) are associated with index year, adjusting by year of diagnosis, sex, age, and stage at diagnosis. Logistic regression models were run to study overall mortality at 2 years, adjusting by the same covariates., Results: The 2017 cohort had a lower mortality odd (odds ratio, 0.93; P = .02) and a significant increase in the average overall costs ( P = .009) than the 2015 cohort. The Tobit regression analysis by cost item showed a very significant increase in the average cost of drugs (coefficient = 5,953, P = .008) for the 2017 cohort, as well as a decrease in the average cost of hospice care (coefficient = -1,822.6, P = .022)., Conclusion: Our study showed a survival improvement for patients with NSCLC as well as an economic burden growth. Physicians should therefore be encouraged to follow new clinical care pathways, while the steadily rising related costs underscore the need for policymakers and health professionals to pursue., Competing Interests: Alessandra BujaResearch Funding: AspiagTravel, Accommodations, Expenses: Sanofi Valentina GuarneriConsulting or Advisory Role: Lilly, Roche, NovartisSpeakers' Bureau: Novartis, LillyTravel, Accommodations, Expenses: Tesaro, Celgene PierFranco ConteConsulting or Advisory Role: Daiichi Sankyo/LillySpeakers' Bureau: Roche/Genentech, Novartis, AstraZeneca, Lilly, Tesaro, Bristol-Myers SquibbResearch Funding: Roche, Novartis, Merck KGaA, Bristol-Myers SquibbExpert Testimony: Roche, AstraZenecaTravel, Accommodations, Expenses: Novartis, Celgene, AstraZeneca, PfizerNo other potential conflicts of interest were reported.

Despite several epidemiologic and preclinical studies supporting the role of diet in cancer progression, the complexity of the diet-cancer link makes it challenging to deconvolute the underlying mechanisms, which remain scantly elucidated. This review focuses on genomic instability as one of the cancer hallmarks affected by diet-dependent metabolic alterations. We discuss how altered dietary intake of metabolites of the one-carbon metabolism, including methionine, folate, and vitamins B and C, can impact the methylation processes and thereby tumorigenesis. We present the concept that the protumorigenic effect of certain diets, such as the Western diet, is in part due to a diet-induced erosion of the DNA repair capacity caused by altered epigenetic and epitranscriptomic landscapes, while the protective effect of other dietary patterns, such as the Mediterranean diet, can be partly explained by their ability to sustain a proficient DNA repair. In particular, considering that diet-dependent alterations of the one-carbon metabolism can impact the rate of methylation processes, changes in dietary patterns can affect the activity of writers and erasers of histone and RNA methyl marks and consequently impair their role in ensuring a proficient DNA damage repair., (©2021 American Association for Cancer Research.)

In March 2020, the COVID-19 pandemic disrupted most of the routine outpatient activities in Italian hospitals and Prevention Departments, including those vaccinations which were not urgent and/or scheduled for children aged 0-6 years. Since June 2020, when the pandemic entered a milder phase, in the alpine Province of Belluno (Veneto, North-Eastern Italy), 12,152 doses of vaccine against tick-borne encephalitis have been administered by means of the innovative "drive-through" modality. No significant adverse events have occurred and popular demand has steadily grown, proving the "drive-through" approach to be safe, efficient and successful., (©2020 Pacini Editore SRL, Pisa, Italy.)

Background: Clinical factors, such as tumor thickness, ulceration and growth phase have a role as prognostic factors for stage I melanoma. However, it is still under debate whether these variables influence the related direct costs. We aimed to investigate which clinical factors represent direct health care "cost drivers" for stage I melanoma., Materials and Method: Analyses were conducted on a cohort of patients diagnosed with stage I melanoma. Differences in the costs incurred by different groups of patients were examined using Mann-Whitney or Kruskal-Wallis non-parametric tests. Log linear multivariate analysis was used to identify the clinical drivers of the total direct costs one and two years after diagnosis. The study was conducted from the perspective of Italy's National Health care System., Results: One year after diagnosis, patients whose melanomas had a Breslow thickness ≥0.8 mmin (compared with those with lower thickness) and a vertical growth phase (compared with those with radial growth) incurred higher costs for hospitalization, as well as higher overall costs. One year after their diagnosis, treatment of patients with stage I melanoma in the vertical growth phase costs 50% more (95% CI: 22-85%) than their counterparts with a radial growth pattern, resulting in an estimated absolute increase of € 256.23. Having a tumor thicker than 0.8 mm prompted an increase of 91% (95% CI: 43-155%) in the costs (€955.24 in absolute terms)., Conclusion: Our data indicate a heterogeneity in the direct costs of stage I melanoma patients during the first year after diagnosis, which can be partly explained by clinical prognostic factors, like tumor thickness and growth pattern., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)

Glyphosate is the best-selling herbicide in the world and in 2015 the International Agency for Research on Cancer listed it among the "probable carcinogens for humans", opening a scientific debate that is still going on. On these premises, in 2016, extraordinary samplings of glyphosate, its metabolite AMPA, and a similar compound, ammonium glufosinate, were carried out in 12 wells of the water network intended for domestic consumption in the territory of the Local Health Unit 2 - District of Pieve di Soligo, Province of Treviso, Veneto region, Italy. The area includes 13 municipalities at high-intensity "Prosecco d.o.c.g." wine production. Traces of glyphosate (maximum reached 0.08 µg/L) and AMPA (maximum reached 0.25 µg/L, beyond the legal limit of 0.1 µg/L for drinking water) were detected in 2 wells supplying an urban area. No samples contained traces of ammonium glufosinate. Following these findings, an inter-municipal order to suspend the use of glyphosate was introduced and then entered definitively in the rural police regulation concerning all the municipalities in the Prosecco d.o.c.g. area, which led to the elimination of glyphosate and AMPA also in the initially contaminated wells. The case shows that high-consumption herbicides can reach the drinking water network of a city surrounded by territories with high agricultural activity. Moreover, the combined intervention of the institutions was fundamental to eliminate a "probable carcinogen" from the urban drinking water and to promote the abandonment of potentially harmful agricultural practices in favor of solutions with reduced environmental and health impact.

Although ΔNp63 is known to promote cancer cell proliferation, the underlying mechanism behind its oncogenic function remains elusive. We report here a functional interplay between ΔNp63 and Δ133p53. These two proteins are co-overexpressed in a subset of human cancers and cooperate to promote cell proliferation. Mechanistically, Δ133p53 binds to ΔNp63 and utilizes its transactivation domain to upregulate GLUT1, GLUT4, and PGM expression driving glycolysis. While increased glycolysis provides cancer cells with anabolic metabolism critical for proliferation and survival, it can be harnessed for selective cancer cell killing. Indeed, we show that tumors overexpressing both ΔNp63 and Δ133p53 exhibit heightened sensitivity to vitamin C that accumulate to a lethal level due to accelerated uptake via overexpressed GLUT1. These observations offer a new therapeutic avenue that could be exploited for clinical applications.